Rapport Therapeutics (RAPP) Competitors

$37.01 -0.94 (-2.48%)

As of 01:56 PM Eastern

RAPP vs. KYMR, ACLX, MIRM, PTGX, and RYTM

Should you buy Rapport Therapeutics stock or one of its competitors? MarketBeat compares Rapport Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rapport Therapeutics include Kymera Therapeutics (KYMR), Arcellx (ACLX), Mirum Pharmaceuticals (MIRM), Protagonist Therapeutics (PTGX), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.

How does Rapport Therapeutics compare to Kymera Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Rapport Therapeutics has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.06, indicating that its stock price is 106% more volatile than the broader market.

Rapport Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
Kymera Therapeutics	$39.21M	172.95	-$311.35M	-$3.57	N/A

Rapport Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Rapport Therapeutics currently has a consensus price target of $54.83, suggesting a potential upside of 48.68%. Kymera Therapeutics has a consensus price target of $118.10, suggesting a potential upside of 43.25%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Rapport Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

In the previous week, Rapport Therapeutics had 3 more articles in the media than Kymera Therapeutics. MarketBeat recorded 13 mentions for Rapport Therapeutics and 10 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.42 beat Rapport Therapeutics' score of 0.35 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	3 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rapport Therapeutics beats Kymera Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Rapport Therapeutics compare to Arcellx?

Rapport Therapeutics (NASDAQ:RAPP) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Rapport Therapeutics has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Arcellx has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

96.0% of Arcellx shares are held by institutional investors. 13.6% of Rapport Therapeutics shares are held by company insiders. Comparatively, 8.4% of Arcellx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Rapport Therapeutics has higher earnings, but lower revenue than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
Arcellx	$22.29M	301.95	-$228.93M	-$4.07	N/A

In the previous week, Rapport Therapeutics had 13 more articles in the media than Arcellx. MarketBeat recorded 13 mentions for Rapport Therapeutics and 0 mentions for Arcellx. Arcellx's average media sentiment score of 1.07 beat Rapport Therapeutics' score of 0.35 indicating that Arcellx is being referred to more favorably in the news media.

Company	Overall Sentiment
Rapport Therapeutics	Neutral
Arcellx	Positive

Rapport Therapeutics currently has a consensus target price of $54.83, suggesting a potential upside of 48.68%. Arcellx has a consensus target price of $111.87, suggesting a potential downside of 2.78%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Rapport Therapeutics is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Arcellx	1 Sell rating(s)	16 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.11

Rapport Therapeutics has a net margin of 0.00% compared to Arcellx's net margin of -1,027.26%. Rapport Therapeutics' return on equity of -24.78% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
Arcellx	-1,027.26%	-55.42%	-36.24%

Summary

Rapport Therapeutics beats Arcellx on 13 of the 16 factors compared between the two stocks.

How does Rapport Therapeutics compare to Mirum Pharmaceuticals?

Rapport Therapeutics (NASDAQ:RAPP) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Rapport Therapeutics has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 9 more articles in the media than Rapport Therapeutics. MarketBeat recorded 22 mentions for Mirum Pharmaceuticals and 13 mentions for Rapport Therapeutics. Mirum Pharmaceuticals' average media sentiment score of 0.62 beat Rapport Therapeutics' score of 0.35 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	3 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
Mirum Pharmaceuticals	$521.31M	12.43	-$23.36M	-$13.61	N/A

Rapport Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Rapport Therapeutics currently has a consensus target price of $54.83, indicating a potential upside of 48.68%. Mirum Pharmaceuticals has a consensus target price of $136.42, indicating a potential upside of 28.38%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Rapport Therapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Mirum Pharmaceuticals beats Rapport Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Rapport Therapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Rapport Therapeutics has lower revenue, but higher earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	143.80	-$130.15M	-$1.81	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

Protagonist Therapeutics presently has a consensus price target of $113.69, suggesting a potential upside of 10.48%. Rapport Therapeutics has a consensus price target of $54.83, suggesting a potential upside of 48.68%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rapport Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 13.6% of Rapport Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Protagonist Therapeutics had 2 more articles in the media than Rapport Therapeutics. MarketBeat recorded 15 mentions for Protagonist Therapeutics and 13 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.35 beat Protagonist Therapeutics' score of 0.22 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rapport Therapeutics	3 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protagonist Therapeutics has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

Rapport Therapeutics has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Rapport Therapeutics	N/A	-24.78%	-23.44%

Summary

Protagonist Therapeutics and Rapport Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Rapport Therapeutics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Rapport Therapeutics. MarketBeat recorded 18 mentions for Rhythm Pharmaceuticals and 13 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.35 beat Rhythm Pharmaceuticals' score of -0.26 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rapport Therapeutics	3 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rapport Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	32.62	-$196.54M	-$3.13	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

Rhythm Pharmaceuticals presently has a consensus price target of $131.81, suggesting a potential upside of 45.94%. Rapport Therapeutics has a consensus price target of $54.83, suggesting a potential upside of 48.68%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Rapport Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Rhythm Pharmaceuticals has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

Rapport Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Rapport Therapeutics' return on equity of -24.78% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Rapport Therapeutics	N/A	-24.78%	-23.44%

Summary

Rapport Therapeutics beats Rhythm Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Get Rapport Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RAPP vs. The Competition

Export

Metric	Rapport Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.78B	$3.33B	$6.24B	$12.30B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-14.28	18.15	20.39	25.31
Price / Sales	N/A	280.54	541.96	72.69
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	3.74	6.67	9.79	6.90
Net Income	-$111.48M	$24.11M	$3.56B	$333.98M
7 Day Performance	-3.05%	3.81%	0.43%	-0.27%
1 Month Performance	0.46%	-3.19%	-0.87%	1.56%
1 Year Performance	277.87%	68.06%	35.95%	32.45%

Rapport Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RAPP Rapport Therapeutics	3.1003 of 5 stars	$37.01 -2.5%	$54.83 +48.2%	+294.1%	$1.77B	N/A	N/A	N/A	Insider Trade
KYMR Kymera Therapeutics	2.3614 of 5 stars	$82.71 -1.1%	$118.70 +43.5%	+184.0%	$6.80B	$51.48M	N/A	170
ACLX Arcellx	2.4781 of 5 stars	$115.07 flat	$111.87 -2.8%	+95.0%	$6.73B	$22.29M	N/A	80	Positive News High Trading Volume
MIRM Mirum Pharmaceuticals	2.5284 of 5 stars	$105.81 +0.0%	$125.25 +18.4%	+150.9%	$6.45B	$521.31M	N/A	140	Analyst Revision
PTGX Protagonist Therapeutics	1.8544 of 5 stars	$99.21 -0.3%	$108.15 +9.0%	+141.1%	$6.38B	$46.02M	N/A	120	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RAPP) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rapport Therapeutics (RAPP) Competitors

RAPP vs. KYMR, ACLX, MIRM, PTGX, and RYTM

How does Rapport Therapeutics compare to Kymera Therapeutics?

Summary

How does Rapport Therapeutics compare to Arcellx?

Summary

How does Rapport Therapeutics compare to Mirum Pharmaceuticals?

Summary

How does Rapport Therapeutics compare to Protagonist Therapeutics?

Summary

How does Rapport Therapeutics compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP vs. The Competition

Rapport Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rapport Therapeutics (RAPP) Competitors

RAPP vs. KYMR, ACLX, MIRM, PTGX, and RYTM

How does Rapport Therapeutics compare to Kymera Therapeutics?

Which has more volatility and risk, RAPP or KYMR?

Which has stronger earnings and valuation, RAPP or KYMR?

Is RAPP or KYMR more profitable?

Do analysts prefer RAPP or KYMR?

Does the media favor RAPP or KYMR?

Summary

How does Rapport Therapeutics compare to Arcellx?

Which has more risk & volatility, RAPP or ACLX?

Do insiders and institutionals have more ownership in RAPP or ACLX?

Which has better earnings & valuation, RAPP or ACLX?

Does the media prefer RAPP or ACLX?

Do analysts prefer RAPP or ACLX?

Is RAPP or ACLX more profitable?

Summary

How does Rapport Therapeutics compare to Mirum Pharmaceuticals?

Which has more risk and volatility, RAPP or MIRM?

Does the media refer more to RAPP or MIRM?

Which has stronger earnings and valuation, RAPP or MIRM?

Is RAPP or MIRM more profitable?

Do analysts rate RAPP or MIRM?

Summary

How does Rapport Therapeutics compare to Protagonist Therapeutics?

Which has stronger valuation and earnings, PTGX or RAPP?

Do analysts rate PTGX or RAPP?

Do institutionals & insiders have more ownership in PTGX or RAPP?

Does the media refer more to PTGX or RAPP?

Which has more risk & volatility, PTGX or RAPP?

Is PTGX or RAPP more profitable?

Summary

How does Rapport Therapeutics compare to Rhythm Pharmaceuticals?

Does the media favor RYTM or RAPP?

Which has higher earnings & valuation, RYTM or RAPP?

Do analysts rate RYTM or RAPP?

Which has more risk & volatility, RYTM or RAPP?

Is RYTM or RAPP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP vs. The Competition

Rapport Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools